Condition
Advanced Cancer, Various, NOS
Total Trials
2
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Tau Treatment As Usual Standard Psychooncological Care
Research Leaders
6 sponsors active, led by Exelixis
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Phase 1 (1)
Trial Status
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT07312760Not ApplicableRecruitingPrimary
Existential Distress in Advanced Cancer: Comparing a Short-term Psychodynamic Psychotherapy (ORPHYS) to Treatment as Usual (TAU)
NCT00884546Phase 1CompletedPrimary
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
Showing all 2 trials
Research Network
Common Treatments
- Tau Treatment As Usual Standard Psychooncological Care1
- Bortezomib1
- Dexamethasone1
- Bms8339231
- Lenalidomide1
Active Sponsors
- Exelixis1
- Bristol-Myers Squibb1
- Wuerzburg University Hospital1
- University of Kassel1
- University Düsseldorf1